Correlation Between Inhibikase Therapeutics and Oncolytics Biotech
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and Oncolytics Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and Oncolytics Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and Oncolytics Biotech, you can compare the effects of market volatilities on Inhibikase Therapeutics and Oncolytics Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of Oncolytics Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and Oncolytics Biotech.
Diversification Opportunities for Inhibikase Therapeutics and Oncolytics Biotech
0.52 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Inhibikase and Oncolytics is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and Oncolytics Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncolytics Biotech and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with Oncolytics Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncolytics Biotech has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and Oncolytics Biotech go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and Oncolytics Biotech
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 1.38 times more return on investment than Oncolytics Biotech. However, Inhibikase Therapeutics is 1.38 times more volatile than Oncolytics Biotech. It trades about 0.02 of its potential returns per unit of risk. Oncolytics Biotech is currently generating about -0.01 per unit of risk. If you would invest 335.00 in Inhibikase Therapeutics on August 24, 2024 and sell it today you would lose (104.00) from holding Inhibikase Therapeutics or give up 31.04% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. Oncolytics Biotech
Performance |
| Timeline |
| Inhibikase Therapeutics |
| Oncolytics Biotech |
Inhibikase Therapeutics and Oncolytics Biotech Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and Oncolytics Biotech
The main advantage of trading using opposite Inhibikase Therapeutics and Oncolytics Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, Oncolytics Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will offset losses from the drop in Oncolytics Biotech's long position.| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
| Oncolytics Biotech vs. Scpharmaceuticals | Oncolytics Biotech vs. Milestone Pharmaceuticals | Oncolytics Biotech vs. Seres Therapeutics | Oncolytics Biotech vs. DiaMedica Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Complementary Tools
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |